Sai Life Sciences: Should You Buy, Hold, or Sell Right Now?
- September 3, 2026
- Posted by: Kunal Singla
- Category: Market
Sai Life Sciences share price Rs 1,605.20 (NSE), a fresh 52-week high, up 1.15% today. 52-week range Rs 783.85 to Rs 1,630 (today). Q1 FY27 profit up 21.2% YoY.
Quick Answer
Sai Life Sciences Ltd share price hit a fresh 52-week high today at around Rs 1,630, more than double its 52-week low of Rs 783.85. Q1 FY27 revenue grew 10.2 percent year on year to Rs 557.83 crore, with net profit up 21.2 percent to Rs 73.29 crore, continuing solid growth for this contract research and manufacturing organisation. The stock trades at a rich 93.2 times earnings against a sector average near 38 times. Growth-focused investors who believe in India’s CRO and CDMO opportunity may find the current momentum reasonable, while valuation-sensitive investors may find the multiple hard to justify.
Sai Life Sciences share price hit a fresh 52-week high today, trading near Rs 1,605 on the NSE, more than double its 52-week low of Rs 783.85. With solid growth in Q1 FY27, investors are asking whether this pharma CRO and CDMO company is a stock to buy near its highs, a hold, or a sell given the very rich valuation.
This Sai Life Sciences stock analysis walks through the Q1 FY27 numbers, valuation against the pharmaceutical services sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Sai Life Sciences
Keep this backdrop in mind when reading the rest of this Sai Life Sciences share price review. Before deciding on Sai Life Sciences share price, it helps to understand the underlying business. Sai Life Sciences Ltd. provides contract research, development and manufacturing services to global pharmaceutical and biotechnology companies, spanning drug discovery, process development and commercial-scale manufacturing of active pharmaceutical ingredients and intermediates.
As a CRO and CDMO business, Sai Life Sciences benefits from global pharmaceutical companies’ continued outsourcing of research and manufacturing activities, a structural trend supporting demand for the company’s integrated discovery-to-commercialisation service offering.
Sai Life Sciences Share Price Today: Key Levels
The table below summarises where Sai Life Sciences share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Sai Life Sciences CMP (NSE) | Rs 1,605.20 |
| Sai Life Sciences CMP (BSE) | Rs 1,606.45 |
| Day’s Change | +1.15% (Rs +18.20), fresh 52-week high |
| 52-Week Low | Rs 783.85 |
| Market Capitalisation | Approximately Rs 33,696 crore |
| NSE Volume (latest session) | 9,02,266 shares |
Sai Life Sciences share price has hit a fresh 52-week high today, having more than doubled from its 52-week low, reflecting strong investor confidence in the company’s CRO and CDMO growth trajectory.
Check the Univest Screener for Live Stock Data
Sai Life Sciences Financial Performance
Track this line item closely if you are following Sai Life Sciences share price closely. The Sai Life Sciences share price trend is closely tied to how these numbers evolve each quarter. Sai Life Sciences reported Q1 FY27 (June 2026 quarter) revenue of Rs 557.83 crore, up 10.2 percent year on year from Rs 506.32 crore, with net profit growing 21.2 percent year on year to Rs 73.29 crore from Rs 60.46 crore. This continued a positive sequential growth trend across recent quarters.
For the full year FY26, the company reported revenue of Rs 2,241.62 crore, up 29.5 percent year on year, with net profit of Rs 348.91 crore, more than doubling from Rs 170.13 crore in FY25, showing the growth trend has been sustained and accelerating over a full year.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 557.83 crore | Rs 73.29 crore | +10.2% revenue, +21.2% profit YoY |
| FY26 (full year) | Rs 2,241.62 crore | Rs 348.91 crore | +29.5% revenue, +105% profit YoY |
Valuation Check: Is Sai Life Sciences Share Price Expensive?
It is one of the clearest signals available on Sai Life Sciences share price today. Any view on Sai Life Sciences share price should start from these valuation multiples. Sai Life Sciences share price currently reflects a price to earnings ratio of about 93.2 times trailing earnings, a significant premium to the broader pharmaceutical services sector average of roughly 38 times. The price to book ratio stands near 13.6 times, supported by a strong 14.05 percent return on equity.
Debt to equity of 0.12 is low. Historically, CRO and CDMO companies benefiting from global pharma outsourcing trends have commanded premium valuations reflecting long-term growth visibility, so the current very rich multiple reflects the market pricing in continued strong execution, which makes sustaining this pace of growth important to justifying the current price.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Sai Life Sciences share price. Sai Life Sciences share price is trading at a fresh 52-week high today, more than double its 52-week low of Rs 783.85, reflecting an exceptionally strong run over the past year. A stock trading at a fresh high, backed by consistent double-digit growth and accelerating full-year profitability, typically signals the market rewarding tangible execution in the company’s core CRO and CDMO business.
Trading volumes remain heavy, so investors should track Sai Life Sciences share price alongside new client contract wins and margin trends in coming quarters, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Sai Life Sciences’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Sai Life Sciences share price more than headline news on some sessions. Sai Life Sciences is a promoter-founded contract research, development and manufacturing organisation serving global pharmaceutical clients. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Sai Life Sciences
- Strong and accelerating growth: Full-year FY26 profit more than doubled year on year, building on strong revenue growth of 29.5 percent, showing sustained execution.
- Structural pharma outsourcing tailwind: Global pharmaceutical companies’ continued outsourcing of research and manufacturing supports long-term demand for Sai Life Sciences’ integrated services.
- Integrated discovery-to-commercialisation offering: The company’s ability to serve clients across the full drug development lifecycle provides a differentiated, sticky service model.
- Fresh 52-week high on heavy volume: The stock reaching a fresh high on heavy trading volume reflects strong, broad-based market interest in the growth story.
Risks and Factors to Watch
- Very rich valuation: A PE of 93.2 times leaves very limited room for disappointment and prices in continued exceptional growth for years to come.
- Client concentration and contract timing: As a CRO and CDMO business, large client contracts and project timing can create variability in quarterly results even with a healthy long-term pipeline.
- Competitive global CRO and CDMO market: Sai Life Sciences competes against both global and domestic contract research and manufacturing organisations for pharmaceutical client business.
- Regulatory and quality compliance risk: As a manufacturer of pharmaceutical ingredients and intermediates, the company faces ongoing regulatory scrutiny and quality compliance requirements across multiple jurisdictions.
Sai Life Sciences Share Price Target: What the Data Suggests
Until then, Sai Life Sciences share price remains best tracked through live, verified data rather than a single fixed number. Sai Life Sciences does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering strong, accelerating growth driven by the structural global pharma outsourcing trend, trading at a very rich premium to the pharmaceutical services sector.
Historically, CRO and CDMO companies benefiting from this outsourcing trend have sustained premium valuations as long as growth continues. Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser given the very high valuation involved.
Sai Life Sciences: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Sai Life Sciences share price right now. The Sai Life Sciences buy or sell decision depends on how much longer you believe the current growth pace can continue.
The case for buying: Growth-focused investors who believe strongly in India’s CRO and CDMO opportunity and see Sai Life Sciences as a key beneficiary may find the current momentum reasonable, provided they accept the very rich valuation.
The case for holding: Existing shareholders who have benefited from the stock’s exceptional run may prefer to stay invested while monitoring client contract wins.
The case for trimming or waiting: Valuation-sensitive investors uncomfortable with a 93.2 times PE multiple may prefer to wait for a larger valuation cushion before committing fresh capital.
Historically, pharma services companies riding structural outsourcing themes have rewarded early investors substantially, but rich valuations can compress sharply if growth slows, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Sai Life Sciences share price reflects a contract research and manufacturing organisation delivering strong, accelerating growth in Q1 FY27, trading at a fresh 52-week high at a very rich premium to the pharmaceutical services sector. Whether that makes the stock a buy, a hold or a sell right now depends on how much longer this exceptional growth pace can continue. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Sai Life Sciences a good stock to buy right now?
Ans. Sai Life Sciences grew Q1 FY27 profit 21.2 percent year on year, building on FY26’s more than doubling of profit, and the stock hit a fresh 52-week high today. The stock trades at a very rich 93.2 times earnings, so it suits growth investors who believe strongly in India’s CRO and CDMO opportunity.
Q2. What is the Sai Life Sciences share price today?
Ans. Sai Life Sciences share price is trading around Rs 1,605 on the NSE, up about 1.15 percent on the day at a fresh 52-week high. The stock’s 52-week low is Rs 783.85.
Q3. What is the Sai Life Sciences share price target?
Ans. Sai Life Sciences does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser given the very high valuation involved.
Q4. What does Sai Life Sciences do?
Ans. Sai Life Sciences provides contract research, development and manufacturing services to global pharmaceutical and biotechnology companies, spanning drug discovery, process development and commercial-scale manufacturing.
Q5. What is Sai Life Sciences’ market capitalisation and PE ratio?
Ans. Sai Life Sciences has a market capitalisation of approximately Rs 33,696 crore and trades at a price to earnings ratio of about 93.2 times, a significant premium to the pharmaceutical services sector average PE of roughly 38 times.
Q6. Why did Sai Life Sciences’ profit more than double in FY26?
Ans. Sai Life Sciences’ full-year FY26 net profit grew from Rs 170.13 crore to Rs 348.91 crore, driven by 29.5 percent revenue growth and improving margins as the company continued to benefit from global pharmaceutical companies’ outsourcing of research and manufacturing activities.
